Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03681561 · ClinicalTrials.gov registry record · Phase 1
Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma
A Phase 1 study of Hodgkin Lymphoma, sponsored by Veronika Bachanova.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 54
- Enrollment target
- 6
- Study locations
NCT03681561 is a Phase 1 study of Hodgkin Lymphoma that is actively recruiting participants, run by Veronika Bachanova. The registered enrollment target is 54 participants, below the 165-participant average among 71 other Hodgkin Lymphoma trials with a reported enrollment target (67% lower). The trial reports 6 study locations across 6 states.
The verdict
NCT03681561, a Phase 1 study of Hodgkin Lymphoma, is actively recruiting participants, sponsored by Veronika Bachanova.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 54 participants
- Enrollment target
- 6
- Study locations
Study Summary
This is a Phase I/II, multicenter, open-label, dose escalation/dose-expansion study to evaluate the tolerability, safety, and the maximum tolerated dose (MTD) of ruxolitinib when given with fixed dose nivolumab in patients with relapsed or refractory classical Hodgkin lymphoma (cHL).
Conditions Studied
Interventions
- DRUG Nivolumab
- DRUG Ruxolitinib
Study Locations (6)
Illinois
- University of Illinois Cancer Center - Chicago
Indiana
- Indiana Melvin and Bren Simon Comprehensive Cancer Center - Indianapolis
Iowa
- University of Iowa Hospitals and Clinics - Iowa City
Minnesota
- University of Minnesota - Minneapolis
Ohio
- Ohio State University Comprehensive Cancer Center - Columbus
Wisconsin
- University of Wisconsin - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2018-09-13 |
| Est. Completion | 2027-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03681561
The ClinicalTrials.gov registry entry for NCT03681561 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 165-participant average among 71 other Hodgkin Lymphoma trials with a reported enrollment target (67% lower). The listed sponsor is Veronika Bachanova, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hodgkin Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which Nivolumab is the first listed.
NCT03681561 reports 6 study locations spanning 6 distinct geographic areas - top geographies include Illinois, Indiana, Iowa.
Frequently Asked Questions
What is clinical trial NCT03681561 about?
NCT03681561 is a clinical study titled "Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma". This is a Phase I/II, multicenter, open-label, dose escalation/dose-expansion study to evaluate the tolerability, safety, and the maximum tolerated dose (MTD) of ruxolitinib when given with fixed dose nivolumab in patients with relapsed or refractory classical Hodgkin lymphoma (cHL).
What is the current status of trial NCT03681561?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 54 participants. The study started on 2018-09-13. Estimated completion is 2027-07.
What conditions does trial NCT03681561 study?
This clinical trial studies the following conditions: Hodgkin Lymphoma.
What interventions are being tested in trial NCT03681561?
The interventions under investigation include: Nivolumab (DRUG), Ruxolitinib (DRUG).
Who is sponsoring clinical trial NCT03681561?
This trial is sponsored by Veronika Bachanova, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03681561 being conducted?
This trial has 6 study locations across Illinois, Indiana, Iowa, Minnesota, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hodgkin Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
RECRUITING · Phase 1
-
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
RECRUITING · Phase 1
-
AZD3470 as Monotherapy and in Combination With Anticancer Agents in Participants With Relapsed/Refractory Haematologic Malignancies.
RECRUITING · Phase 1
-
ATLCAR.CD30.CCR4 for CD30+ HL ATLCAR.CD30.CCR4 Cells
RECRUITING · Phase 1
-
Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma
RECRUITING · Phase 1
-
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.